COMMUNIQUÉS West-GlobeNewswire

CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
04/03/2024
MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused [...]
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04/03/2024
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of [...]
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
04/03/2024
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better [...]
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
04/03/2024
BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of [...]
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
04/03/2024
DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
04/03/2024
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more [...]
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
04/03/2024
SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
04/03/2024
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to [...]
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
04/03/2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
MIMEDX Announces Appointment of Two New Independent Directors
04/03/2024
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as [...]
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
04/03/2024
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full [...]
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
04/03/2024
Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages 2-5 with atopic dermatitis New patient-reported outcomes including pruritus data from two [...]
Orion Corporation: Managers’ transactions – Olli Huotari
04/03/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MARCH 2024 at 13.00 EET Orion Corporation: Managers’ transactions – Olli Huotari Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers’ transactions – Satu Ahomäki
04/03/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MARCH 2024 at 13.00 EET Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Orion Corporation: Managers’ transactions – Liisa Hurme
04/03/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MARCH 2024 at 13.00 EET Orion Corporation: Managers’ transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
The Ensign Group Acquires Skilled Nursing Facility in Kansas
04/03/2024
SAN JUAN CAPISTRANO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]
The Ensign Group Acquires Two Skilled Nursing Facilities in Colorado
04/03/2024
SAN JUAN CAPISTRANO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Orion Corporation: Managers’ transactions – Jari Karlson
04/03/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 4 MARCH 2024 at 13.00 EET Orion Corporation: Managers’ transactions – Jari Karlson Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
04/03/2024
50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg ( [...]

Pages